Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study
Rongbin Qi, Xinyu Fu, Yingying Yu, Hailing Xu, Mo Shen, Susu He, Dongqing Lv
Topics & Concepts
MedicineCohortInternal medicineOncologyEpidermal growth factor receptorLung cancerProgression-free survivalT790MBevacizumabChemotherapyRetrospective cohort studyCancerGefitinibLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment